Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market December 4, 2025 – 7:45 a.m. CET Regulated information Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market Mortsel, Belgium – December 4, 2025 – 7:45 a.m. CET Agfa today announced that it plans to implement additional measures to adjust the cost base of its traditional film activities to the accelerated global market decline. These measures are an extension to the plan that was announced in Novem...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt 4 december 2025 – 7:45 uur CET Gereglementeerde informatie Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt Mortsel, België – 4 december 2025 – 7u45 Agfa kondigde vandaag aan dat het van plan is bijkomende maatregelen te nemen om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de versnelde achteruitgang van de wereldwijde markten. Deze...
After three quarters, Agfa's 9M25 “Mature Business” (Radiology and Film DPC) sales dropped -6.4% y/y, driven by the accelerating medical film decline. While its “Growth Engines” (HealthCare IT, Digital Printing Solutions, Green Hydrogen Solutions) are intended to offset this, they also fell -0.9% y/y in the first nine months. We remain cautious (Hold; €1.0 Target Price) until strategic measures deliver and growth engines regain momentum.
Agfa's 3Q25 continued decline in medical film was even stronger than expected (€ 257m 3Q25 sales vs € 275m KBCS & CSS). Although the growth in cloud/SaaS in HealthCare IT all the divisions were below our and CSS forecasts as well on top-line as on REBIT-margins. The increase in Digital Printing & Chemicals was not sufficiently offsetting the impact from the decline in medical film and from cloud transition in HealthCare IT. Despite good cost control, REBIT decreased to -4m, mainly due to the d...
The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Regulated information November 13, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q3 2025: continued decline in medical film, strong growth cloud and SaaS in HealthCare IT, soft markets in Digital Print & Chemicals Group performance: Top line decrease of 7.1% (-4.7% currency comparable): increase in Digital Printing & Chemicals not sufficiently offsetting impact from decline in medical...
De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Gereglementeerde informatie 13 november 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het derde kwartaal van 2025: voortdurende achteruitgang in medische film, sterke groei cloud en SaaS in HealthCare IT, zwakkere markten in Digital Print & Chemicals Groepsprestatie: Omzetdaling van 7,1% (-4.7% zonder wisselkoerseffecten): stijging ...
Two Directors at Crescent NV bought/sold 95,490,000 shares at between 0.007EUR and 0.007EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over...
The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Regulated information August 27, 2025 - 7:45 a.m. CET The Agfa-Gevaert Group in Q2 2025: strong HealthCare IT performance, stable Digital Print & Chemicals performance – further decline in medical film Group performance: Strong HealthCare IT performance and stable Digital Print & Chemicals performance not sufficiently offsetting the continued fast decline in medical filmAdjusted EBITDA decreased...
De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Gereglementeerde informatie 27 augustus 2025 - 7:45 uur CET De Agfa-Gevaert Groep in het tweede kwartaal van 2025: Sterke prestatie HealthCare IT, stabiele prestatie Digital Print & Chemicals – verdere achteruitgang medische film Groepsprestatie: Sterke prestatie van HealthCare IT en stabiele prestatie van Digital Print & Chemicals volstaan niet om de ...
Agfa-Gevaert NV signs new revolving credit facility - Regulated information - Contains inside information August 1, 2025 – 6.00 PM CET Regulated information - Contains inside information Agfa-Gevaert NV signs new revolving credit facility Mortsel, Belgium – August 1, 2025 – 6.00 p.m. CET Agfa-Gevaert NV has signed a new 3 year revolving credit facility of 180 million euro. The new facility will run until August 1, 2028. This new revolving credit facility will be used for working capital and general corporate purposes. It will replace the existing...
Agfa-Gevaert NV tekent nieuwe doorlopende kredietfaciliteit - Gereglementeerde informatie – Bevat voorwetenschap 1 augustus 2025 – 18u00 CET Gereglementeerde informatie – Bevat voorwetenschap Agfa-Gevaert NV tekent nieuwe doorlopende kredietfaciliteit Mortsel, België – 1 augustus 2025 – 18u00 CET Agfa-Gevaert NV heeft een nieuwe voor 3 jaar geldende doorlopende kredietfaciliteit getekend voor een bedrag van 180 miljoen euro. De nieuwe faciliteit loopt tot 1 augustus 2028. Deze nieuwe doorlopende kredietfaciliteit zal gebruikt worden voor werkkapitaal en algemene bedrijfsdoeleinden. Ze...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.